ESSA Pharma/EPIX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About ESSA Pharma

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.

Ticker

EPIX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

David Parkinson

Employees

50

Headquarters

Vancouver, Canada

ESSA Pharma Metrics

BasicAdvanced
$299M
Market cap
-
P/E ratio
-$0.63
EPS
1.82
Beta
-
Dividend rate
$299M
1.81558
$11.67
$2.58
59K
32.891
-18.71%
-19.14%
-19.12%
2.244
2.244
4.37%

What the Analysts think about ESSA Pharma

Analyst Ratings

Majority rating from 4 analysts.
Buy

ESSA Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$0
NaN%
Net income
-$8.9M
50.85%
Profit margin
0.00%
NaN%

ESSA Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 6.38%
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
-$0.17
-$0.12
-$0.14
-$0.20
-
Expected
-$0.20
-$0.21
-$0.17
-$0.19
-$0.25
Surprise
-12.82%
-42.86%
-18.84%
6.38%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for ESSA Pharma stock?

ESSA Pharma (EPIX) has a market cap of $299M as of June 15, 2024.

What is the P/E ratio for ESSA Pharma stock?

The price to earnings (P/E) ratio for ESSA Pharma (EPIX) stock is 0 as of June 15, 2024.

Does ESSA Pharma stock pay dividends?

No, ESSA Pharma (EPIX) stock does not pay dividends to its shareholders as of June 15, 2024.

When is the next ESSA Pharma dividend payment date?

ESSA Pharma (EPIX) stock does not pay dividends to its shareholders.

What is the beta indicator for ESSA Pharma?

ESSA Pharma (EPIX) has a beta rating of 1.82. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the ESSA Pharma stock price target?

The target price for ESSA Pharma (EPIX) stock is $19, which is NaN% below the current price of $. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell ESSA Pharma stock

Buy or sell ESSA Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing